OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Clinical Dermatology is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Alcohol and Smoking Cessation as Potential Modulators for Smoking-Associated Psoriasis Risk in Postmenopausal Women: The Women’s Health Initiative	238
The Current State of Systemic Therapy of Metastatic Uveal Melanoma	173
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review	118
Prognostic Biomarkers in Evolving Melanoma Immunotherapy	101
Economic Burden of Chronic Hand Eczema: A Review	99
Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions	93
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments	91
The Burden of Pediatric Psoriasis: A Systematic Review	91
Disease Duration in Patients Recruited to Psoriasis Phase III Trials: A Systematic Review	91
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials	84
Performance of Staging Systems for Non-head and Neck Cutaneous Squamous Cell Carcinoma	72
Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know	66
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study	66
Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments	65
Agreement Between Nail Psoriasis Severity Index Scores by a Convolutional Neural Network and Dermatologists: A Retrospective Study at an Academic New York City Institution	64
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroi	61
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?	61
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review	61
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data	61
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks	61
Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology	57
Pathophysiology of Generalized Pustular Psoriasis	56
Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion	55
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation	54
Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study	53

Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”	52
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment	48
Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature	47
Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry	47
Lessons Learned from Orthopedics: A Call to Action for More Rigorous Platelet-Rich Plasma Hair Loss Clinical Trials	46
Ethnic Differences of Palmoplantar Pustulosis: A Systematic Review	45
Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis	45
Disease Modification in Psoriasis: Future Prospects for Long-Term Remission	45
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management	44
A Practice Approach to Acne Fulminans in Adolescents	43
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis	42
Correction to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment Hist	41
Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment	41
Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives	41
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa	40
Patient and Public Involvement in Dermatology Research: A Review	40
Multiple Keratoacanthomas Associated with Genetic Syndromes: Narrative Review and Proposal of a Diagnostic Algorithm	40